Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PHenotype-based RApid SEquencing of Guideline-directed Medical Therapy for Heart Failure With Reduced Ejection Fraction (PHRASE-HF): A Multicentre, Prospective, Non-interventional Study to Examine Outcomes of Rapid In-hospital Implementation of GDMT and Its Translation From Discharge Into Routine Care

NCT06675552 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06675552
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06675552 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PHenotype-based RApid SEquencing of Guideline-directed Medical Therapy for Heart Failure With Reduced Ejection Fraction (PHRASE-HF): A Multicentre, Prospective, Non-interventional Study to Examine Outcomes of Rapid In-hospital Implementation of GDMT and Its Translation From Discharge Into Routine Care
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Active, not recruiting
Start date
November 15, 2024
Completion date
June 30, 2027
Enrollment
338 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

cardiovascular disease, heart disease, heart failure, heart failure, systolic